Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer
| Autor: | Marcus A. Neubauer, Timothy Lopez, Howard A. Burris, Paul D. Swanson, Jordan Berlin, J. Randolph Hecht, Maureen Reiner, Glenn Buchanan, Edith P. Mitchell, Jennifer Gansert |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Colorectal cancer Antineoplastic Agents medicine.disease_cause Metastasis Young Adult Predictive Value of Tests Internal medicine Biomarkers Tumor medicine Carcinoma Humans Panitumumab Epidermal growth factor receptor Neoplasm Metastasis Adverse effect Aged Aged 80 and over biology business.industry Antibodies Monoclonal Cancer Middle Aged Prognosis medicine.disease ErbB Receptors Treatment Outcome Immunology biology.protein Female KRAS Colorectal Neoplasms business medicine.drug |
| Zdroj: | Clinical Cancer Research. 16:2205-2213 |
| ISSN: | 1557-3265 1078-0432 |
| Popis: | Purpose: Panitumumab, a fully human anti–epidermal growth factor receptor (EGFR) monoclonal antibody, is approved as monotherapy for the treatment of metastatic colorectal cancer. We evaluated the association of tumor EGFR expression levels with outcomes in patients with chemorefractory metastatic colorectal cancer. Experimental Design: Two phase II, multicenter, single-arm, open-label studies enrolled chemorefractory patients with tumors expressing low/negative (1-9%/ Results: A total of 203 patients (Low/Negative EGFR) and 185 patients (High EGFR) enrolled in the studies. The overall response rate was 5.7% [95% confidence interval (95% CI), 2.6-10.5] in patients with low/negative EGFR and 4.2% (95% CI, 1.6-9.0) in patients with high EGFR; the response rate at week 16 was 4% in both studies (all partial responses). Median PFS times were 8.1 weeks (95% CI, 7.1-12.6), 8.1 weeks (95% CI, 7.4-11.1), and 7.3 weeks (95% CI, 7.1-7.6) in patients with negative, low, and high levels of EGFR expression, respectively. PFS and OS were longer in patients with wild-type KRAS than those with mutant KRAS. As expected, most adverse events were skin related. Conclusions: These studies confirm previous reports that tumor EGFR expression levels are not associated with efficacy with an anti-EGFR antibody and that anti-EGFR antibody therapy should be limited to those patients whose tumors express wild-type KRAS. Clin Cancer Res; 16(7); 2205–13. ©2010 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|